The clinical and laboratorial evaluation of transdermal ketamine, fentanyl, clonidine or their combination in chronic low back pain

Avaliação clínica e laboratorial da cetamina transdérmica, do fentanil transdérmico, da clonidina transdérmica ou suas associações na dor lombar crônica

Evaluación clínica y de laboratorio de cetamina transdérmica, del fentanyl transdérmico, de la clonidina transdérmica o de sus asociaciones en el dolor lumbar crónico

Gabriela Rocha Lauretti  
Márcio Matsumoto  
Anita Leocádia de Mattos  
Vera Lanchote  
Newton Lindolfo Pereira

ABSTRACT
Objectives: chronic low back pain may result in central sensitization, with involvement of different receptors. The aim of this study was to evaluate the analgesic action of transdermal (T) ketamine (a NMDA antagonist), clonidine (an α2-agonist), fentanyl (an opioid agonist), or their combination in chronic low back pain. Methods: after the institutional approval and informed consent signature, 54 patients were prospectively randomized into 6 groups. Each patient had two of the T preparations applied in different arms. The effect of either T ketamine (1 mg/h), T clonidine (25 μg/h) or T fentanyl (25 μg/h), combined with T placebo (CloG, KetG and FenG); or the combination of T ketamine and clonidine

RESUMO
Objetivos: a dor lombar crônica pode resultar em sensibilização central, com a participação de diferentes tipos de receptores. O objetivo deste estudo foi avaliar a ação analgésica por via transdérmica (T) do fentanil, cetamina, clonidina ou suas associações para o alívio da dor lombar crônica. Métodos: após aprovação do Comitê de Ética em Pesquisa e assinatura do termo de consentimento livre e esclarecido, 54 pacientes foram avaliados de forma prospectiva, aleatória e duplamente-encoberta, sendo divididos em 6 grupos. Cada paciente recebeu duas preparações por via transdérmica, aplicadas em braços diferentes (T cetamina (1 mg/h), T clonidina (25 μg/h) ou T fentanil (25 μg/h), associados a T placebo (CloG, KetG e FenG); ou a
INTRODUCTION

Persistent nociception following low back pain may lead to transcriptional and translational changes in the spinal cord and brain, resulting in central sensitization and pain. It involves different spinal processes, and the participation of N-methyl-D-aspartate (NMDA)\(^1\), \(\alpha\)-2-adrenergic\(^2\) and opioid receptors\(^3\) may play a role. The purpose of this paper was to evaluate the analgesic action of transdermal (T) ketamine (a NMDA antagonist), clonidine (an \(\alpha\)-2-agonist), fentanyl (an opioid agonist), or their combina-
tion in chronic non-radicular low back pain. The study was conducted and limited to duration of assessment because of our interest in defining the best drugs association, in order to direct us for future and long-time evaluation studies. Plasma measurement of noradrenaline, a predictive stress neurotransmitter\(^4\), was carried out to corroborate any analgesic effect from the T systems applied.

**METHODS**

After the Ethics Committee approval and written informed consent signature, 54 ASA status II patients suffering from chronic low back pain were computer-randomized to one of six groups and prospectively evaluated using a placebo-controlled double-blind design to examine analgesia and adverse effects (n=9). All patients located for the study design presented complaints of chronic intractable non-radicular low back pain secondary to disc degeneration, degenerative arthritis in the intervertebral joints and osteophytes, were under physiotherapy treatment and had been previously submitted to a sequence of three weekly caudal blocks with 10 mg of depot-dexamethasone combined with 30 μg of clonidine and 40 mg of lidocaine (with added saline to a 10-ml final volume) as part of our routine protocol at the Pain Clinic, two months before the study day. All patients were taken 25-50 mg amitriptyline at bedtime and 20 mg omeprazol in the morning. Oral 100 mg ketoprofen tablet was prescribed as rescue analgesic up to twice daily. However, from the day before the study, no rescue analgesic was allowed, in order to evaluate the analgesic effect of the proposed T drugs.

The concept of visual analog scale (VAS), which consisted of a 10 cm line with 0 corresponding to “no pain at all” or “not sedated at all” and 10 to “the worst possible pain” or “most sedated” was introduced before the study. Patients stayed in rest condition in a quiet, temperature- and humidity-controlled room. The study was carried out in the Pain Clinic, in the mornings, with the patient sited in a comfortable long-chair, and the median cephalic or the median basilic vein of the arm was heparinized for blood collection. Although patients complained of daily pain at rest and moving conditions, pain was assessed only during resting state, according to the study protocol.

Each T drug was applied in each arm, in a clean area, and every patient had applied two of the T preparations, one in the right arm and the other in the left arm, in the right and left deltoid muscles. The effects of T ketamine (1 mg/h), T clonidine (25 μg/h) or T fentanyl (25 μg/h), combined with T placebo (CloG, KetG and FenG); or the combination of T ketamine and clonidine (Ket-CloG), T fentanyl and ketamine (Fen-KetG), or T fentanyl and clonidine (Fen-CloG) were evaluated (Table 1). One anesthetiologist blind to the treatments applied the T drugs. The placebo and the T systems were individually prepared and tested for the pharmacokinetic profile by the Industrial Laboratory of the Faculty of Pharmaceutical Sciences of Ribeirão Preto, Universidade de São Paulo, and contained the same vehicle and similar physical and chemical properties. The dosages chosen for the different T drugs were based on previous experiences with T ketamine\(^5\), T fentanyl\(^5\) and T clonidine\(^6\) and on published data regarding T fentanyl\(^7\). The T ketamine cream was developed and tested for controlled delivery of approximately 1 mg/h ketamine during the study period\(^8\). Thirty minutes after the T ketamine application, detectable levels of plasmatic ketamine were observed. By three and six hours, plasma levels of ketamine were near 0.05 and 0.08 μg/mL, respectively. The T clonidine system was developed to deliver 25 μg/h of the active drug. The process to describe the ideal dose of T clonidine was carried out in our Pain Clinic. Different IV doses were initially evaluated in patients suffering from chronic pain, and the minor dose that resulted in reduced pain scores was IV 30 μg every three hours. Subsequent studies conducted by our group determined that 40% of the total clonidine dose from the cream preparation was available as plasma free drug. It means that in three hours, although 75 μg of clonidine was disposable through T application, only 30 μg of clonidine (correspondent to 40% of 75 μg) was available in the plasma, and near 60 μg in six-hour evaluation. Related to the T fentanyl cream, it was developed and tested for controlled delivery of 25 μg/h and, after 3 and 6 hours, its plasma concentration was respectively 0.21 ng/mL and 0.54 ng/mL.

Pain was evaluated by VAS pain scores (0-10 cm) and by plasma noradrenalin measurement prior (time 0-h), 3 hours after (time 3-h) and 6 hours after (time 6-h) the T drugs application. Plasma measurements of noradrenaline were done through High Performance Liquid Chromatography (HPLC) at the Faculty of Pharmaceutical Sciences of Ribeirão Preto, Universidade de São Paulo. After withdraw of 10-ml blood in order to avoid any dilution at the site of collection, 5-ml of venous blood was collected at the times: 1) 0-h (just prior to the T systems application), 2) 3-h and 3) 6-h after T creams application. The samples were transposed in heparinized tubes and plasma separated by centrifugation. The plasma samples were stored at -70°C until drug assay by HPLC. Sedation was evaluated by VAS (0-10 cm) scores at the times 0-h, 3-h and 6-h. Mean blood pressure, pulse rate and respiratory frequency were evaluated at 30-minute interval. Pulse oximetry was continuously evaluated, and additional oxygen was available if O\(_2\) saturation was inferior to 90%.

**TABLE 1 - Groups**

<table>
<thead>
<tr>
<th>Group</th>
<th>Transdermal system for controlled liberation of the active drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>CloG</td>
<td>Placebo + clonidine 25 μg/h</td>
</tr>
<tr>
<td>KetG</td>
<td>Placebo + ketamine 1 μg/h</td>
</tr>
<tr>
<td>FenG</td>
<td>Placebo + fentanyl 25 μg/h</td>
</tr>
<tr>
<td>Ket-CloG</td>
<td>Ketamine 1 μg/h + clonidine 25 μg/h</td>
</tr>
<tr>
<td>Fen-KetG</td>
<td>Fentanyl 25 μg/h + ketamine 1 μg/h</td>
</tr>
<tr>
<td>Fen-CloG</td>
<td>Fentanyl 25 μg/h + clonidine 25 μg/h</td>
</tr>
</tbody>
</table>

Clo: clonidine; Ket: ketamine; Fen: fentanyl; G: group
decrease in mean arterial pressure superior to 15% below initial baseline was treated by incremental doses of ephedrine, 5 mg IV. Decreases in heart rate below 50 bpm were treated with incremental doses of atropine, 0.5 mg IV. The number of patients having nausea (of any degree) or vomiting at any point was reported. Nausea greater than 4/10 cm at any time or vomiting during the study were treated initially with metoclopramide 10 mg IV followed by ondansetron 4 mg IV, if necessary. Hallucination was treated with incremental IV midazolam. Any other adverse events were noted and treated, if necessary. At the end of the 6-h evaluation, IV 100 mg ketoprofen was available at patient request.

**Statistical analysis**

The number of subjects was based on preliminary experimental data. For this pilot study, we hypothesized that T administration of two drugs combination would enhance by 100% the analgesic effect of the drug alone, in order to get the best combination among the different drugs. If we would have estimated a standard deviation for this prospective power analysis an 80% and an \( \alpha \) value of 0.05, these assumptions would have required at least 6 patients in each group to achieve a 100% decrease in VAS scores.

The normality of the distributions was assessed using the Shapiro-Wilk’s test. Groups were compared for demographic data (age, weight, height) and duration of chronic pain by ANOVA. Incidence of adverse events, gender, ASA status and adjuvant drug used were compared between groups by \( \chi^2 \) testcorrected for multiple comparisons. Blood pressure, heart rate, respiratory rate and VAS scores were compared between groups by two-way ANOVA for repeated measures. Tukey analysis was applied to decrease the probability of type I error. The plasma values of noradrenaline and the number of rescue analgesics were compared by means of Kruskal-Wallis test, followed by the Newman-Keuls test, while data within the same group were compared by Friedman test followed by the Wilcoxon rank sum test. The value of \( p<0.05 \) was considered significant. Data are expressed as mean±SD, otherwise stated.

**RESULTS**

Fifty-one patients completed the study protocol. One patient from the FenG and one from the Fen-CloG were excluded due to incomplete collected data. A second patient from the Fen-CloG gave up his participation in the middle of the study, for he was in a hurry to get the bus. The six groups showed no differences regarding ASA status, gender, age, weight, height and length in time of pain complaint (\( p>0.05 \), Table 2). There were no differences concerning mean blood pressure, pulse rate and respiratory frequency measured at 30-min interval among and within groups (\( p>0.05 \)). Pulse oximetry was always maintained above 92% and no patients needed supplemental \( O_2 \) during the study period.

The data with reference to the pain VAS scores is described in Table 3. The analysis within groups revealed that the VAS pain score at 6-h was smaller compared to the 0-h to the FenG, CloG, KetG and Ket-CloG (\( p<0.02 \)). The groups receiving T fentanyl combined with either T ketamine or T clonidine (Fen-KetG and Fen-CloG) showed a significantly higher improvement between 0-h and 6-h (\( p<0.01 \)). The comparison among groups revealed that all groups were similar at 0-h and 3-h. At 6-h, both Fen-CloG and Fen-KetG had smaller VAS scores compared to the administration of the correspondent T drug alone (\( p<0.05 \), Table 3).

The plasma noradrenaline data is described in Table 4. The statistical analysis showed that administration of T fentanyl alone (FenG) resulted in plasma noradrenaline decrease at 6-h compared to itself at 0-h and 3-h (\( p<0.01 \)), while the association of T fentanyl with T clonidine resulted in plasma noradrenaline decrease at 3- and 6-h, compared to itself at 0-h and compared to other groups at 3-h and 6-h (\( p<0.01 \)). The combination of both T ketamine and clonidine (Ket-CloG) did not result in a better analgesic profile (\( p>0.05 \)).

All groups, except the Ket-CloG, were similar regarding adverse effects (\( p>0.05 \)). One patient from the CloG was sedated (VAS 4-cm), and other complained of heating, sweating, headache and blurred vision at 6-h. The T drugs were cleaned from the skin and the patients kept in observation for two extra hours. An IV access was obtained and 500 mL lactate solution was infused during this period. No other pharmacological treatment was necessary and, by the time of discharge, the symptoms had ceased. In the KetG, one patient complained of nausea (VAS 5-cm) at 4-h and was medicated with 10 mg ketoprofen was available at patient request.

**TABLE 2 - Demographic data**

<table>
<thead>
<tr>
<th></th>
<th>ASA (II/III)</th>
<th>Gender (M/F)</th>
<th>Weight (kg)*</th>
<th>Age (years)*</th>
<th>Height (cm)*</th>
<th>Duration of pain complaint (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CloG</td>
<td>6/3</td>
<td>2/7</td>
<td>72±17</td>
<td>47±13</td>
<td>162±6</td>
<td>7±2</td>
</tr>
<tr>
<td>KetG</td>
<td>5/4</td>
<td>2/7</td>
<td>65±11</td>
<td>48±14</td>
<td>160±7</td>
<td>8±4</td>
</tr>
<tr>
<td>FenG</td>
<td>5/3</td>
<td>2/6</td>
<td>63±14</td>
<td>51±18</td>
<td>157±9</td>
<td>7±3</td>
</tr>
<tr>
<td>Ket-CloG</td>
<td>6/2</td>
<td>2/6</td>
<td>72±14</td>
<td>41±14</td>
<td>162±10</td>
<td>7±3</td>
</tr>
<tr>
<td>Fen-KetG</td>
<td>6/3</td>
<td>3/6</td>
<td>68±14</td>
<td>42±13</td>
<td>167±6</td>
<td>8±2</td>
</tr>
<tr>
<td>Fen-CloG</td>
<td>4/3</td>
<td>3/4</td>
<td>68±13</td>
<td>46±7</td>
<td>163±6</td>
<td>7±2</td>
</tr>
</tbody>
</table>

\( p>0.05 \); Clo: clonidine; Ket: ketamine; Fen: fentanyl; G: group.

*Data expressed as mean±SD.
mg IV metoclopramide. In the FenG, no adverse effects were observed during the study period. Two patients from the Ket-FenG were mildly sedated at 6-h (VAS 2-cm). One patient from the Fen-CloG complained of transitory nausea (VAS 3-cm) at 4-h, but no pharmacological treatment was necessary. No other adverse effects were noted.

The group Ket-Clo was statistically different concerning the sedation (p<0.02). Seven among nine patients were sedated by 6-h (VAS 5-8 cm), although respiratory frequency and pulse oximetry did not differ within and among groups. One of the patients complained about headache at 3-h, hence 100 mg IV ketoprofen was infused over 20-min. Another patient had hypertension (150/95 mmHg) at 6-h, and the T drugs were cleaned from the skin of both arms. The patient was kept in close observation and blood pressure measured at 5-min interval for an extra 45-min, when blood pressure was 138/83 mmHg. She had no clinical discomfort during this period. There were no complaints of hallucination or other adverse effects from patients.

**DISCUSSION**

The results of the actual study demonstrated that any T drug alone resulted in clinical analgesia based on the smaller pain VAS scored at 6-h, and that combination of T fentanyl with either T ketamine or T clonidine resulted in even smaller pain VAS scores at 6-h in comparison to the administration of the correspondent T drug alone. The analgesia following T fentanyl, in accordance to other studies, was further corroborated by decrease of plasma noradrenaline levels, when applied alone or combined with T clonidine.

The literature reveals that opioids are commonly prescribed for chronic back pain and may be efficacious for short-term pain relief, as long-term efficacy for up to 16 weeks is unclear. In addition, substance use disorders are common in patients who take opioids for back pain, and aberrant medication-taking behaviors occurred in up to 24% of the cases. Among opioids, T fentanyl was described as superior to oral morphine for chronic low back pain. Although daily analgesia was similar between the two opioids, T fentanyl resulted in less constipation and greater pain relief at night. The drugs of the study were chosen based on actual data regarding pain processes. Inotropic NMDA receptors play a crucial role at pain pathways, and their modulation may have potential for therapeutic utility in categories of persistent pain, including neuropathic, inflammatory or joint-related pain that may contribute to low back pain. Ketamine would act by antagonizing the NMDA receptor and expression patterns in nociceptive pathways. The second drug studied, the α2-agonist clonidine, was described to exert analgesia by depressing the synaptic plasticity in spinal dorsal horn, via activation of muscarinic receptor-NO-cGMP pathway and, finally, the participation of opioids in central plasticity is well known.

However, although clinical evaluation revealed to some extent benefit of all T drugs tested, the laboratorial data revealed that administration of T fentanyl alone (FenG) resulted in plasma noradrenaline decrease at 6-h compared to itself at the 0-h. Although the minimum effective concentration of T fentanyl in serum (0.63 ng/mL) was achieved at 11.3 ± 4.9 hours after application, fentanyl as a cream preparation took less than six hours, and was indirectly supported by the decreased plasma noradrenaline level. In addition, the association of T fentanyl with clonidine resulted in plasma noradrenaline decrease even at 3- and 6-h, compared to either drug alone or to the other groups, corroborating to the clinical data. It has been demonstrated that stress-produced hormones (such as noradrenaline) in the blood serum served as indirect criteria of the functional activity of the endogenic antinociceptive structures before and after the treatment. It is a fact that interaction of adrenoreceptors with α2-opioids is clear in inflammation, and that endogenous α2-adrenergic systems play an important role in the modulation of the effectiveness of opioids during inflammation process, what could explain the actual results. However, patients who received
only T clonidine (CloG) did not show any decrease in plasma noradrenaline levels. Although α2-adrenergic receptor activation with clonidine in rats experiencing hyperalgesia inhibited noradrenaline release, and clonidine resulted in dose-dependent noradrenaline decrease, by 6-h evaluation the dose used resulted in no evident decrease of noradrenaline by itself. However, the same dose further enhanced noradrenaline decrease after T fentanyl at 3-h evaluation.

In the present study, the combined administration of the opioid fentanyl and ketamine resulted in analgesia by 6-h, which was evidenced by lower VAS pain scores compared to T application of one of the study’s drugs alone. In accordance, metabotropic glutamate receptors and morphine demonstrated to possess synergistic drug interaction for antinociception during phase 2 in the formalin test in rats. The application of T ketamine alone (KetG) was analgesic by itself, in accordance to others, and result in greater plasma noradrenaline levels, but apparently blunted the decrease in the Fen-KetG at 6-h. The absence of any decrease in plasma noradrenaline level was probably secondary to ketamine. Ketamine induces sympathomimetic action by impairment of both excytosis and noradrenaline uptake, plasma noradrenaline increased by 20% after bolus IV injection of ketamine in volunteers and, in dogs, while ketamine used alone caused increased noradrenaline concentration, the association of the α2-agonist medetomidine prevented or blunted this change. By the time, cortisol levels were not measured, as patients received cumulative depot-dexamethasone, which may have compromised the hypothalamic-pituitary axis. Besides, plasma cortisol serum concentration was described as similar regarding healthy control and chronic low back pain.

Interestingly, the combination of both T ketamine and clonidine (Ket-CloG) did not result in a better analgesic profile compared to the correspondent drug alone and resulted in excessive sedation during the 6-h evaluation. The data demonstrated that the combined administration of ketamine and clonidine did not enhance analgesia, but enhanced adverse effects, which was disappointing to us. The rate of opioid prescription in our practice for chronic noncancerous pain is less than 5%, as we are among the Pain Specialists that do not approve opioids as first-line therapy in nonmalignant chronic pain, and there was some degree of expectative regarding the combination of ketamine and clonidine as the “best association” for this purpose. This pilot study was indeed conducted and limited to duration of assessment of 6 hours because of our interest in defining the best drugs association in order to direct us for future and long-time evaluation studies, and our greatest expectation was indeed the among non-opioid drugs ketamine and clonidine. In the mouse hot plate-test, the potency of clonidine was found to increase with co-administration of ketamine, but not dextromethorphan. Although this association was controversial in acute pain, the continuous intrathecal administration of S(+)ketamine with clonidine resulted in adequate pain relief in a patient suffering from intractable neuropathic cancer pain. In the current study, a pure placebo group was not included, what could theoretically affect the decrease in the VAS scores clinically obtained, but could not have blunted the noradrenaline serum data found.

In conclusion, all studied drugs resulted in clinical analgesia (VAS) at 6-h, and the association of fentanyl with either clonidine or ketamine resulted in even smaller VAS scores in comparison to the drugs alone. However, T fentanyl analgesia was corroborated by lower plasma noradrenaline levels at 6-h when applied alone, or at 3-h when combined with T clonidine in patients suffering from chronic low back pain. Whether the mechanism of action is central, peripheral, or both, is something that could not be determined based on these data.

REFERENCES


Correspondence
Gabriela Rocha Lauretti
Rua Maestro Joaquim Rangel, 644
CEP 14025-610 – Ribeirão Preto (SP), Brazil
Fone: (16) 3602-2211
E-mail: grlauret@fmrp.usp.br